As per a recent study released by Maximize Market Research, titled, “Neurology Clinical Trials Market,” The Neurology Clinical Trials Market, size was valued at USD 6.26 Billion in 2024 and the total Neurology Clinical Trials revenue is expected to grow at a CAGR of 6.5% from 2025 to 2032, reaching nearly USD 10.36 Billion.
Neurology Clinical Trials Market Overview:
The neurology clinical trials market is set for robust growth, underpinned by a surge in neurological disorders globally and increasing investment in novel therapeutics. Clinical trials focused on conditions like Alzheimer’s, Parkinson’s, epilepsy, stroke, and multiple sclerosis are expanding in number and sophistication. Advances in biomarkers, imaging, and patient recruitment methods are making trials faster, more precise, and more patient-friendly. As healthcare systems and research institutions respond to unmet needs in neurology, both public and private sectors are pushing to bring better treatments from the lab to the clinic.
Download a Free Sample Report Today :https://www.maximizemarketresearch.com/request-sample/171139/
Neurology Clinical Trials Market Dynamics
One of the main drivers is the increasing prevalence of neurological disorders worldwide, especially among aging populations. Conditions like Alzheimer’s disease, dementia, Parkinson’s disease, and others are rising in both developed and emerging regions, increasing the urgency for new, effective treatments. This creates a larger patient base for clinical trials and a greater need for innovative therapeutic interventions.
Another significant dynamic is technological innovation in trial design and execution. The adoption of decentralized clinical trials, hybrid models, remote patient monitoring, and digital health tools is helping bring down costs, improve patient access, and increase efficiency. Biomarkers and advanced imaging are enabling earlier go/no-go decisions, which accelerates trial timelines. Additionally, biologics, gene therapies, and personalized medicine are opening new frontiers, especially in neurology where many conditions have complex etiologies and limited treatment options.
Neurology Clinical Trials Market Outlook and Future Trends :
Looking forward, neurology trials are likely to see increased focus on rare and currently underserved indications, such as Huntington’s disease, ALS (amyotrophic lateral sclerosis), and certain neurodegenerative or genetic disorders. The pipeline for gene therapy and cell therapy in neurology is growing, which suggests that early-phase trials will expand rapidly.
Another trend is greater regulatory support and collaboration. Governments, non-profit organizations, and industry are increasingly funding neurological research, refining regulatory pathways (for example fast-track or breakthrough designations), and facilitating cross-border trials. All this will help reduce time to market and improve the portfolio of treatments available for patients with neurological conditions. Patient centricity — better trial participant experience, remote follow ups, etc. — will also become more standard.
Neurology Clinical Trials Market Regional Insights:
North America continues to lead the neurology clinical trials market, thanks to its strong research infrastructure, high levels of healthcare expenditure, active participation of pharmaceutical and biotech companies, and favorable regulatory environment. Many key players are based in the U.S., and there is robust support from government and research institutions. This region dominates both in trial numbers and in trial spend.
Asia-Pacific is emerging as the fastest-growing region in terms of trial activity and investment. Factors contributing include improving healthcare infrastructure, growing awareness of neurological disorders, increasing costs and delays in some western markets that push sponsors to consider more cost-effective regions, and expanding CRO (Contract Research Organization) capacities. India, China, South Korea among others are seeing strong growth in both early- and late-phase neurology trials.
Neurology Clinical Trials Market Segmentation
by Phase
1. Phase I
2. Phase II
3. Phase III
4. Phase IV
by Study Design
1. Interventional
2. Observational
3. Expanded Access
by Indication
1. Huntington’s Disease
2. Epilepsy
3. Parkinson’s Disease (PD)
4. Stroke
5. Traumatic Brain Injury (TBI)
6. Amyotrophic Lateral Sclerosis (ALS)
7. Muscle regeneration
8. Others
Some of the current players in the Neurology Clinical Trials Market are:
1. Supernus Pharmaceuticals, Inc. (US)
2. Adamas Pharmaceuticals (US)
3. Eli Lilly and Company (US)
4. Aurora Health Care (US)
5. AbbVie Inc. (US)
6. Medtronic (US)
7. Zydus Group (India)
8. Athira Pharma, Inc. (US)
9. Annovis Bio ( (US)
10. Biogen (US)
11. Merck & Co., Inc. (US)
12. IQVIA (US)
13. Covance (US)
14. Medpace (US)
15. Charles River Laboratories (US)
About Maximize Market Research:
Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.
Contact Maximize Market Research:
MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
🖂 [email protected]
